Extavia and Abnormal behaviour - a phase IV clinical study of FDA data

Summary:

Abnormal behaviour is reported as a side effect among people who take Extavia (interferon beta-1b), especially for people who are male, 50-59 old, have been taking the drug for 2 - 5 years also take Ativan, and have Secondary progressive multiple sclerosis.

The phase IV clinical study analyzes which people have Abnormal behaviour when taking Extavia. It is created by eHealthMe based on reports of 4,879 people who have side effects when taking Extavia from the FDA, and is updated regularly.

What is Extavia?

Extavia has active ingredients of interferon beta-1b. It is often used in multiple sclerosis. eHealthMe is studying from 4,888 Extavia users. Check the latest studies of Extavia.

What is Abnormal behaviour?

Abnormal behaviour is found to be associated with 1,801 drugs and 2,209 conditions by eHealthMe. Check the latest studies of Abnormal behaviour.

On Jun, 20, 2026

4,879 people reported to have side effects when taking Extavia.
Among them, 16 people (0.33%) have Abnormal behaviour.

Among these 16 people:

How long have people been on Extavia when they have Abnormal behaviour? *

What is the gender of people who have Abnormal behaviour when taking Extavia? *

female: 46.67 %
male: 53.33 %

What is the age of people who have Abnormal behaviour when taking Extavia? *

What are other drugs people take besides Extavia? *

What are other side effects people have besides Abnormal behaviour? *

Depression: 6 people, 37.50%
Insomnia (sleeplessness): 5 people, 31.25%
Fatigue (feeling of tiredness): 4 people, 25.00%
Fall: 3 people, 18.75%
Dyspnea (difficult or laboured breathing): 3 people, 18.75%
Weight Decreased: 3 people, 18.75%
Stress And Anxiety: 3 people, 18.75%
Injection Site Pain: 3 people, 18.75%
Influenza Like Illness: 3 people, 18.75%
Quality Of Life Decreased: 2 people, 12.50%

What are the existing conditions these people have? *

Secondary Progressive Multiple Sclerosis (a stage of ms which comes after relapsing remitting ms in many cases): 2 people, 12.50%
Relapsing-Remitting Multiple Sclerosis (reoccurrence of an inflammatory disease in which the insulating covers of nerve cells in the brain and spinal cord are damaged): 1 person, 6.25%
Insomnia (sleeplessness): 1 person, 6.25%
Depressive Symptom: 1 person, 6.25%
Depression: 1 person, 6.25%

* Approximation only. Some reports may have incomplete information.

Do you take Extavia and have Abnormal behaviour?

- Check whether Abnormal behaviour is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Extavia:

Extavia (4,888 reports)

Browse all side effects of Extavia:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Abnormal behaviour:

Abnormal behaviour (1,801 drugs)

Browse all the conditions that are associated with Abnormal behaviour:

Abnormal behaviour (2,209 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on interferon beta-1b (the active ingredients of Extavia) and Extavia (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.